The self-funded vaccination here refers to self-funded vaccines, and it is necessary to have self-funded vaccines for pneumonia in children.
Currently there are 2 types of pneumococcal disease vaccines on the market in China: one is the 23-valent pneumococcal polysaccharide vaccine, and the other is the 13-valent pneumococcal polysaccharide conjugate vaccine. 23-valent vaccine is derived from pneumococcal podocarboxylic polysaccharides, which is difficult to produce sufficient and long-lasting antibodies in infants and young children less than 2 years of age, and is recommended for only high-risk groups of 2 years of age and above who are at high risk of pneumococcal infections.
The active ingredient of the 13-valent vaccine is the product of covalent combination of pneumococcal podocarp polysaccharide and proteins, which covers most of the pneumococcal serotypes that lead to serious diseases in children under 5 years old, and induces longer-lasting antibodies and better protection, so the 13-valent vaccine is recommended for infants and young children as a priority.
Pediatric pneumonia is the leading cause of death among children under 5 years of age in China, and the pneumonia vaccine is the most effective means of preventing pneumococcal infections. Parents are advised, if their financial situation permits, to give their children the self-funded vaccine for childhood pneumonia.